Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes.
作者信息
Sehra Devindra, Sehra Sudhish
出版信息
J Assoc Physicians India. 2011 Nov;59:744; author reply 744.
PMID:22616349
Abstract
摘要
相似文献
1
Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes.
J Assoc Physicians India. 2011 Nov;59:744; author reply 744.
2
Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
J Assoc Physicians India. 2011 Apr;59:237-45.
3
[Use of vildagliptin from an internal disease specialists point of view].
Vnitr Lek. 2013 Apr;59(4):322-4.
4
[Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
Nihon Yakurigaku Zasshi. 2010 Nov;136(5):299-308. doi: 10.1254/fpj.136.299.
5
Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Prescrire Int. 2013 May;22(138):121.
6
Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Diabetes Obes Metab. 2009 May;11 Suppl 2:1-2. doi: 10.1111/j.1463-1326.2008.01032.x.
7
Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Expert Opin Pharmacother. 2012 Jun;13(9):1377-84. doi: 10.1517/14656566.2012.667078. Epub 2012 Mar 7.
8
Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
Curr Top Med Chem. 2008;8(17):1545-52. doi: 10.2174/156802608786413519.
9
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Horm Metab Res. 2007 Nov;39(11):826-9. doi: 10.1055/s-2007-991172.
10
[The value of incretin based therapies].
Dtsch Med Wochenschr. 2009 May;134(20):1062-6. doi: 10.1055/s-0029-1222570. Epub 2009 May 6.
Zotero 插件